Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a memory drug break the grip of Anorexia's rigid habits?

NCT ID NCT06518941

Disease control Sponsor: New York State Psychiatric Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests whether donepezil, a medication used for memory, can help adults with anorexia nervosa weaken the strong habits that drive restrictive eating. Ten participants will receive the drug for up to 8 weeks while staying in an inpatient unit, with weekly check-ins to monitor side effects. Researchers will also measure changes in habit strength and food preferences to see if the approach is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
donepezil
What this could lead to
If donepezil proves tolerable and shows promise, it could offer a new medication to help people with anorexia nervosa break rigid eating habits and improve recovery.
What could go wrong
This is a very small, early-stage trial focused on feasibility and safety, not effectiveness. Donepezil may cause side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study (Clinical interview). 3. Aged 18-60 years (Clinical interview). 4. Diagnosed with anorexia nervosa (EDA-5). 5. BMI ≥ 15 kg/m2 (Clinical team medical record) Exclusion Criteria: 1. Score of High Risk on the Columbia Suicide Severity Scale (C-SSRS). 2. Pregnancy (Serum pregnancy test on admission). 3. Current diagnosis of schizophrenia, schizophreniform disorder, bipolar (type I), or substance use disorder (SCID). 4. Bradycardia (below 60 bpm) (vital signs measurement by the clinical team) 5. Corrected QT interval (QTc) greater than 480 ms at baseline (EKG). 6. Antipsychotic medication (antidepressants at a stable dose are allowed) (clinical interview). 7. Known allergic reactions to components of the donepezil (e.g., known hypersensitivity to donepezil hydrochloride) (clinical interview). 8. History of peptic ulcer disease (clinical interview). 9. History of arrhythmia (clinical interview).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anorexia nervosa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Anorexia anorexia nervosa Feeding and Eating Disorders Habits

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anorexia nervosa

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • New York State Psychiatric Institute

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.